A5013138522- Diabetes Treatment and Management
- Diabetes Management and Research
- Cardiovascular Function and Risk Factors
- Metabolism, Diabetes, and Cancer
- Medication Adherence and Compliance
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmacology and Obesity Treatment
- Heart Rate Variability and Autonomic Control
- Liver Disease and Transplantation
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Parkinson's Disease Mechanisms and Treatments
- Respiratory and Cough-Related Research
- Biosimilars and Bioanalytical Methods
- Childhood Cancer Survivors' Quality of Life
- Liver Disease Diagnosis and Treatment
- Diet and metabolism studies
- Sarcoidosis and Beryllium Toxicity Research
- Hematopoietic Stem Cell Transplantation
- Drug-Induced Hepatotoxicity and Protection
- Acute Lymphoblastic Leukemia research
Glenmark Pharmaceuticals (India)
2024
Sun Pharma Advanced Research (India)
2024
Children's Hospital of Philadelphia
2020
Abbott (India)
2017-2019
Abstract Background Obesity is a chronic metabolic disease of global concern, often associated with Type 2 Diabetes Mellitus (T2DM). Global guidelines recommend holistic approach for T2DM management by addressing the comorbidities. Here, we have conducted post-hoc evaluation Liraglutide biosimilar Phase III trial on weight reduction and glycaemic benefits in Indian patients obesity comparison to reference liraglutide. Methods We analysis evaluated HbA1c improvement (BMI > 25 kg/m ) from...
Abstract Background: Teneligliptin has shown better efficacy, tolerability and reduced associated complications in patients with type 2 diabetes mellitus (T2DM) chronic kidney disease (CKD). The aim of this study was to evaluate the effect on renal function glycemic control Indian T2DM CKD a real-world setting. Methodology: This retrospective, observational that included 377 from 4 sites across India. Details prescriptions laboratory investigations individual patient were recorded. Primary...
The aim of this study was to understand patient adherence, satisfaction, and experience with the smaller sized metformin 500 mg prolonged release (PR) tablet that has been manufactured help technological advancement (Gluformin I mg), in comparison extended-release (ER) tablet, patients type 2 diabetes mellitus (T2DM).In postmarketing observational study, T2DM who were on a stable dose PR for at least 1 month had previously received ER recruited from 50 sites India. medication adherence...
Background: In patient of T2DM and HF, reduced ejection fraction (HFrEF) constitutes the majority HF cases, posing significant risk mortality. NYHA classification, recommended in global guidelines, independently predicts SGLT2i have shown to reduce incidence hospitalization for HF. Hence, this study was planned evaluate effectiveness Remogliflozin improving class patients with Methods: prospective, multicentre study, 250 HFrEF having Class I III, were enrolled. 125 allocated each (R)...
Background: Lobeglitazone, a novel TZD was recently approved in India for T2DM, has limited real-world data. This study assessed the effectiveness and safety of Lobeglitazone 0.5 mg once daily settings. Methods: Data captured from medical records patients after obtaining independent ethics committee approval 16 different sites across India. The primary outcome % change HbA1c at week 12. Secondary outcomes were changes fasting blood sugar (FBS), post-prandial (PPBS), lipid, liver renal...
Background: Biosimilar of Liraglutide developed in India has demonstrated non-inferiority terms safety, efficacy and quality compared to reference biologic. Basis this biosimilar been approved for management T2DM. Data generated Indian obese T2DM was further analyzed see & safety with Methods: This post hoc analysis assessed the biologic Indians. Aim assess mean change glycemic parameters from baseline week 24 both groups. Results: Total 179 Obese patients (BMI 25 kg/m2 above) were...
Abstract Aims The ICMR INDIAB-17 study revealed a diabetes prevalence of 11.4% in India, emphasizing the need for effective treatment glycemic control. A Phase IV was conducted to evaluate safety and efficacy Fixed Dose Combination (FDC) Remogliflozin, Metformin Vildagliptin (RMV) Type 2 Diabetes Mellitus (T2DM) patients uncontrolled on plus SGLT2 inhibitor or DPP4 dual therapy. Methods total 215 (mean age: 46.4 years; 64% male, 36% female) were enrolled across multiple centers India....
Background: Hepatic encephalopathy (HE) is a complex, reversible neuropsychiatric syndrome. The present study evaluated the clinical effectiveness and safety of lactulose retention enema for treatment Grade 3 or 4 HE (West Haven Criteria, WHC) in Indian patients.Methods: This retrospective, open-label, uncontrolled cohort was conducted at three centers India. Patients either gender (18-65 years) admitted to hospital with liver cirrhosis having were included. primary endpoint evaluate...